Nine different antibody–drug conjugates (ADCs) are currently approved as cancer
treatments, with dozens more in preclinical and clinical development. The primary goal of …

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a
monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the …

An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which
results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously …

Antibody–Drug Conjugates (ADCs) are now established as a major class of therapeutics for
the clinical treatment of cancer. The properties of the linker between the antibody and the …

Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The
antibody–drug conjugate linker molecule determines both the efficacy and the adverse …

Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …

The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …

The primary purpose of ADCs is to increase the efficacy of anticancer medications by
minimizing systemic drug distribution and targeting specific cells. Antibody conjugates …

Safety and efficacy constitute the major criteria governing regulatory approval of any new
drug. The best method to maximize safety and efficacy is to deliver a proven therapeutic …